Coya Therapeutics Reports Q1 2024 Net Loss of $5.1M and Cash of $36.0M, Advances Pipeline

Coya Therapeutics, Inc.

2024-Q1 EPS reported -$0.35 revenue$126,838

Net loss was $5.1M for Q1 2024 vs $2.7M in Q1 2023; R&D expenses rose to $3.1M from $1.2M.
Cash and cash equivalents totaled $36.0M as of March 31, 2024, providing runway into 2026.
IND filing for COYA 302 in ALS expected in 2Q24, with Ph. 2 trial initiation thereafter.
Pipeline expanded to include Frontotemporal Dementia, Parkinson’s, and Alzheimer’s diseases.
Licensed next-generation immune modulatory biologics from University of Nebraska Medical Center in Feb 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Coya Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $5.1 million for the three months ended March 31, 2024.

Period: the quarter ended March 31, 2024
Net income: Net loss was $5.1 million for the three months ended March 31, 2024
Result: reported results

Exact text from the filing

Net loss was $5.1 million for the three months ended March 31, 2024, compared to net loss of $2.7 million for the three months ended March 31, 2023.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-057018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.